Could removing certain immune cells prevent a deadly transplant complication?

NCT ID NCT03779854

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell transplant. The trial aims to see if this approach is safe and effective, with about 68 participants receiving either the modified cells or standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE BIPHENOTYPIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia acute leukemia of ambiguous lineage acute lymphoblastic leukemia acute myeloid leukemia acute undifferentiated leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm Burkitt lymphoma CD4+/CD56+ hematodermic neoplasm chronic monocytic leukemia GATA2 Deficiency lymphoblastic lymphoma mast cell leukemia mixed phenotype acute leukemia myelodysplastic syndrome with excess blasts myelodysplastic syndrome with excess blasts-1 myeloid leukemia Myeloproliferative Disorders myeloproliferative neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LEUKEMIA ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE UNDIFFERENTIATED LEUKEMIA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM BLASTS UNDER 25 PERCENT OF BONE MARROW NUCLEATED CELLS BLASTS UNDER 5 PERCENT OF BONE MARROW NUCLEATED CELLS BURKITT LEUKEMIA CHRONIC MONOCYTIC LEUKEMIA LYMPHOBLASTIC LYMPHOMA MAST CELL LEUKEMIA MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Locations

Children's Healthcare of Atlanta
NOT_YET_RECRUITING

Atlanta, Georgia, 30329, United States
Children's Hospital of Los Angeles
RECRUITING

Los Angeles, California, 90027, United States
Children's Hospital of Pittsburgh of UPMC
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States
Children's National Medical Center
WITHDRAWN

Washington D.C., District of Columbia, 200100, United States
Cleveland Clinic Foundation
COMPLETED

Cleveland, Ohio, 44195, United States
Dana Farber / Boston Children's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center)
NOT_YET_RECRUITING

Cleveland, Ohio, 44106, United States
University of Iowa/Holden Comprehensive Cancer Center
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.